One of the strangest manufacturing statistics of the decade comes out of Ukraine. As reported by Olena Kryzhanivska’s Ukraine’s Arms Monitor, the DrukArmy initiative unites roughly 2,500 volunteers with personal 3D printers, working from apartments and garages, shipping more than 110,000 “cold” munition bodies per month across 128 design variants as of early 2026. Cold meaning inert: printed componentry without energetic fill. No factory. No production line. No quality department walking the floor.
The obvious question is why quality didn’t collapse. The answer is the most useful manufacturing lesson I’ve encountered in years, and it has almost nothing to do with war.
What a design transfer package actually contains
Look closely at how that volunteer network operates and a structure appears. Every participant receives a curated list of verified components with purchase links. The design configuration is frozen; files, firmware, and settings arrive as a package with detailed instructions. Training is mandatory before anyone builds. Finished units never go straight to the field; each one passes through centralized testing first. And the genuinely dangerous step, the energetic fill, never left professional hands at all. The distributed layer only ever touched cold parts. (Oboronka’s independent reporting on the initiative documents the same structure and the same output figures.)
Strip away the context and what remains is familiar to anyone who has worked in regulated product development: a frozen configuration, controlled inputs, qualified operators, documented work instructions, a risk-based decision about which operations may never leave the centre, and a final verification gate. That is a design transfer package. In medical device development, design transfer is the controlled handoff of a finished design into manufacturing: the documented package of specifications, verified sourcing, work instructions, operator training, and acceptance criteria that lets production faithfully reproduce what engineering validated. Ukraine industrialized design transfer and made it portable, then handed it to thousands of strangers, and it held.
This is worth stating carefully, because the lazy reading of that story is “distribute the work and test everything at the end.” That reading deserves to be dismissed, and anyone from the medical device or diagnostics world will dismiss it on sight. You cannot test quality into a product. Final testing in the Ukrainian system is the last gate, never the strategy. The strategy is everything upstream of it: the work arrives already controlled, so the test at the end confirms rather than compensates. Distributed manufacturing fails wherever inspection is asked to make up for process control that stayed home.
Why distributed manufacturing matters beyond defence
Distributed manufacturing is production spread across multiple smaller nodes close to demand, rather than concentrated in one plant.
Manufacturing is being pulled toward localization from every direction at once: tariffs and trade friction, sovereign content requirements, regional regulatory expectations, customers who want supply within their borders, and logistics that no longer behave. The instinctive response is to think in buildings. A second plant. A regional facility. Reshoring.
The more interesting shift is that production is dissolving into networks: more nodes, closer to demand, each doing a bounded slice of the work. And that shift quietly changes what a manufacturer’s most valuable asset is. The question stops being “how good is our factory” and becomes “can our product be built by someone else, somewhere else, at qualified quality, without us standing over it?”
For most companies the honest answer is no, and the reasons were baked in years earlier: tribal knowledge that never became documentation, processes that were tuned rather than characterized, components specified by habit instead of by verified source, test methods that live in one technician’s hands. None of that is visible until the day you need a second site, a contract manufacturer, a licensee, or a regional partner. Then all of it is visible at once.
Where distributed manufacturing is already landing
The pattern shows up in three recurring situations: a regulated product facing local-manufacturing expectations, an overloaded plant that cannot absorb new volume, and a scale-up that cannot justify a second facility.
A diagnostics company wins interest from a market with local-manufacturing expectations. The instrument works beautifully. But the build knowledge lives in the heads of the original team, and standing up a compliant second line means reconstructing, from scratch, everything a production package should have captured the first time.
An industrial OEM has one overloaded plant and a customer asking for volumes that plant cannot absorb. The fastest capacity is someone else’s, a qualified partner an hour from the customer, but only if the product can travel as a controlled package rather than as a six-month absorption project. We’ve seen this pattern across our industrial programs: capacity is rarely the true constraint; transferability is.
A cleantech scale-up cannot justify a second facility and should not build one. What it can do is design its next-generation product so that final assembly, configuration, and test can run at partner sites near demand, while the processes that genuinely require central control stay central. That partitioning, deciding what distributes and what must never, is a risk-based engineering decision, and it is exactly the same logic that keeps sterile processing in the cleanroom.
What does not distribute
Not everything distributes, and pretending otherwise is how this idea curdles into hype. Precision fabrication, wet chemistry, validated special processes, and most component manufacturing stay where the economics and the controls live. Even Ukraine, under existential pressure, still imports its circuit boards. What distributes well is assembly, configuration, personalization, test, repair, and service, the work closest to the customer. The companies getting this right are not scattering factories; they are partitioning their products.
When transferability is actually decided
Whether a product can be built across a network is determined in CAD, at the design stage, not at the point production moves.
Here is the part I care about most, because it is where the outcome is actually determined. Whether a product can be built across a network is decided at the design stage: in architecture choices, in how modules partition, in whether processes get characterized or merely tuned, in whether the design transfer package is treated as a deliverable or an afterthought. By the time localization pressure arrives, the answer has usually been locked in for years.
At Inertia we’ve built our whole model around that observation: decisions made early either carry forward cleanly or surface later as cost, delay, and rework. It’s why we treat strategy, development, and manufacturing as one connected decision system, why manufacturing readiness is usually where we start the conversation, and why local, networked production has been on our own roadmap as a service concept.
If your product may ever need to be built in a second place, by a second team, under someone else’s roof, the time to engineer for that is now, while it still costs almost nothing. The teams that will handle the next decade of localization pressure gracefully are the ones treating manufacturing knowledge as a product in its own right: versioned, controlled, and ready to travel.
